Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
Posted inAllergy & Immunology Dermatology news

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment

A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable safety profile with minimal systemic absorption, offering a promising new topical JAK inhibitor option.
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
Posted inAllergy & Immunology Dermatology news

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both treatments showing favorable safety profiles.
Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD
Posted inDermatology Gastroenterology news

Beyond the Gut: Understanding the High Prevalence and Clinical Impact of JAK Inhibitor-Induced Acne in IBD

An international multicenter study reveals that acne is a frequent adverse event in IBD patients treated with JAK inhibitors, particularly upadacitinib. The research highlights dose-dependency, significant psychosocial impacts, and the critical need for proactive dermatological management in clinical practice.